Koers Protagonist Therapeutics Inc Nasdaq
Aandelen
US74366E1029
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- PTS | - |
Omzet 2024 * | 270 mln. 0 248 mln. | Omzet 2025 * | 120 mln. 0 110 mln. | Marktkapitalisatie | 1,85 mld. 0 1,7 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 77 mln. - 70,86 mln. | Nettowinst (verlies) 2025 * | 2 mln. - 1,84 mln. | EV/omzet 2024 * | 5,2 x |
Nettoliquiditeiten 2024 * | 442 mln. 0 406 mln. | Nettoliquiditeiten 2025 * | 677 mln. 0 623 mln. | EV/omzet 2025 * | 9,76 x |
K/w-verhouding 2024 * |
27,7
x | K/w-verhouding 2025 * |
-32,5
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98% |
Recentste transcriptie over Protagonist Therapeutics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Dinesh Patel
CEO | Chief Executive Officer | 67 | 01-12-08 |
Asif Ali
DFI | Director of Finance/CFO | 50 | 18-04-22 |
Chief Tech/Sci/R&D Officer | - | 01-07-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Lewis Williams
BRD | Director/Board Member | 74 | 08-06-17 |
Harold Selick
CHM | Chairman | 69 | 01-02-09 |
Daniel Swisher
BRD | Director/Board Member | 61 | 26-10-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+33,37% | 49,46 mld. | |
+1,55% | 42,58 mld. | |
+49,11% | 42,49 mld. | |
-4,22% | 29,09 mld. | |
+11,57% | 26,61 mld. | |
-21,00% | 18,64 mld. | |
+7,36% | 13,16 mld. | |
+28,30% | 12,55 mld. | |
+23,80% | 12,1 mld. |
- Beurs
- Aandelen
- Koers PTGX
- Koers